9月23日 - ** 生物技术公司Immunovant（IMVT.O）的股价在盘前交易中下跌4.5%，至35.6美元
** 若跌势持续，该股开盘价将创下三个多月来的新低
** 由于该药物在研究的主要目标上未能达到统计学显著性，公司计划停止 (link) 针对皮肤型红斑狼疮（CLE）的IMVT-1402药物研发
** CLE是一种自身免疫性皮肤病，会引起皮疹和皮损，通常由日晒诱发
** IMVT最大股东Roivant Sciences ROIV.O 的股价下跌2.9%
** 17家券商中有13家对该股评级为“买入”或更高，4家为“持有”；目标价中位数为47美元
** 截至上一交易日收盘，IMVT股价年内累计上涨46.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.